I make a donation

REMINDER

Evaluate the effect of eplerenone on cardiovascular mortality and morbidity in patients having a myocardial infarct under treatment

Terminée

Bourses ACTION & PHRA 2022

Colloquium "La cardiologie préventive : nouveautés" (mardi 1er avril 2025)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

P&R Agenda
Au programme prochainement...

objectif

Impact of eplerenone on cardiovascular outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

date de réalisation

2010

nombre de patients

1013

nombre de centres participants

68 centers in 11 countries

type de financement

Private (Pfizer)

Référence

NCT01176968

A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction (REMINDER)

Study Description

We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

source clinicaltrials.gov

Publication

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure : the Randomized Double-Blind Reminder Study
Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent, Faiez Zannad, REMINDER Investigators
Publicated in European Heart Journal

Presentation

ESC2017 - ALBATROSS & REMINDER update
powerpoint pdf

Autres études

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....

AMPHIBIA

En cours

Acute Myocarditis registry with Prognostic, Histologic, Immunologic, Biological, Imaging and clinical Assessment : The AMPHIBIA registry

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.